Citius Oncology Enters into Distribution Services Agreement with Cardinal Health

Agreement supports the upcoming launch of LYMPHIR for the treatment of cutaneous T-cell lymphoma
CRANFORD, N.J., June 9, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that it has entered into a distribution services agreement with Cardinal Health (NYSE: CAH), a leading provider of pharmaceutical and specialty pharmaceutical distribution services in the United States.
This agreement is designed to help provide access to LYMPHIR™ (denileukin diftitox-cxdl), an innovative immunotherapy FDA-approved for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL), in support of its anticipated U.S. commercial launch.
"This agreement marks a key step forward in our launch readiness efforts," said Leonard Mazur, Chairman and CEO of Citius Oncology and Citius Pharmaceuticals. "Cardinal Health's proven distribution capabilities will help ensure LYMPHIR reaches healthcare providers and patients efficiently and reliably, as we work to build a robust commercial distribution network."
Under the agreement, Cardinal Health will serve as an authorized distributor of record for Citius Oncology providing specialty pharmaceutical distribution services.
About LYMPHIR™ (denileukin diftitox-cxdl)
LYMPHIR is a targeted immune therapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL) indicated for use in Stage I-III disease after at least one prior systemic therapy. It is a recombinant fusion protein that combines the IL-2 receptor binding domain with diphtheria toxin fragments. The agent specifically binds to IL-2 receptors on the cell surface, causing diphtheria toxin fragments that have entered cells to inhibit protein synthesis. After uptake into the cell, the DT fragment is cleaved and the free DT fragments inhibit protein synthesis, resulting in cell death. Denileukin diftitox-cxdl demonstrated the ability to deplete immunosuppressive regulatory T lymphocytes (Tregs) and antitumor activity through a direct cytocidal action on IL-2R-expressing tumors.
In 2021, denileukin diftitox received regulatory approval in Japan for the treatment of CTCL and PTCL. Subsequently, in 2021, Citius acquired an exclusive license with rights to develop and commercialize LYMPHIR in all markets except for Japan and certain parts of Asia. LYMPHIR was approved by the FDA in August 2024.
About Cutaneous T-cell Lymphoma
Cutaneous T-cell lymphoma is a type of cutaneous non-Hodgkin lymphoma (NHL) that comes in a variety of forms and is the most common type of cutaneous lymphoma. In CTCL, T-cells, a type of lymphocyte that plays a role in the immune system, become cancerous and develop into skin lesions, leading to a decrease in the quality of life of patients with this disease due to severe pain and pruritus. Mycosis Fungoides (MF) and Sézary Syndrome (SS) comprise the majority of CTCL cases. Depending on the type of CTCL, the disease may progress slowly and can take anywhere from several years to upwards of ten to potentially reach tumor stage. However, once the disease reaches this stage, the cancer is highly malignant and can spread to the lymph nodes and internal organs, resulting in a poor prognosis. Given the duration of the disease, patients typically cycle through multiple agents to control disease progression. CTCL affects men twice as often as women and is typically first diagnosed in patients between the ages of 50 and 60 years of age. Other than allogeneic stem cell transplantation, for which only a small fraction of patients qualify, there is currently no curative therapy for advanced CTCL.
INDICATION
LYMPHIR is an IL2-receptor-directed cytotoxin indicated for the treatment of adult patients with r/r Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy.
IMPORTANT SAFETY INFORMATION
BOXED WARNING: CAPILLARY LEAK SYNDROME
Capillary leak syndrome (CLS), including life-threatening or fatal reactions, can occur in patients receiving LYMPHIR. Monitor patients for signs and symptoms of CLS during treatment. Withhold LYMPHIR until CLS resolves, or permanently discontinue based on severity.
WARNINGS AND PRECAUTIONS
Capillary Leak Syndrome
LYMPHIR can cause capillary leak syndrome (CLS), including life-threatening or fatal reactions. CLS was defined in the clinical trials as the occurrence of at least 2 of the following symptoms at any time during LYMPHIR therapy: hypotension, edema, and serum albumin <3 g/dL. These symptoms were not required to occur simultaneously to be characterized as capillary leak syndrome.
As defined, CLS occurred in 27% of patients in the pooled population across 3 clinical trials, including 8% with Grade 3. There was one (0.8%) fatal occurrence of CLS. Of the patients with CLS, 22% had recurrence. The majority of CLS events (81%) occurred within the first 2 cycles of treatment. The median time to onset from Cycle 1, Day 1 was 6.5 days (range: 1 to 77), the median duration of CLS was 14 days (range: 2 to 40), and 75% of patients had resolution. The most common symptoms included edema, hypoalbuminemia, and hypotension. Pleural effusion, pericardial effusion, and dehydration also occurred.
Regularly assess patients for weight gain, new onset or worsening of edema, dyspnea, and hypotension (including orthostatic changes). Monitor serum albumin levels prior to the initiation of each cycle of therapy and more often as clinically indicated.
Withhold, reduce dose, or permanently discontinue based on severity. If LYMPHIR is withheld, resume LYMPHIR following resolution of CLS and when serum albumin is greater than or equal to 3 g/dL.
Visual Impairment
LYMPHIR can cause serious visual impairment, including changes in visual acuity and color vision. In the pooled population across 3 clinical trials, visual impairment occurred in 9%, with Grade 1 in 8% and Grade 2 in 1%. The most commonly reported symptom was blurred vision. Of the patients with visual impairment, 67% had resolution of their visual impairment.
Perform baseline ophthalmic examination and monitor as clinically indicated. If patients experience symptoms of visual impairment, such as changes in visual acuity, changes in color vision, or blurred vision, refer for ophthalmologic evaluation.
Withhold LYMPHIR until visual impairment resolves or permanently discontinue based on severity.
Infusion-Related Reactions
LYMPHIR can cause serious infusion-related reactions. Infusion-related reactions were reported in 69% of patients in the pooled population across 3 clinical trials of patients who received LYMPHIR, with Grade 3 infusion-related reactions in 3.4% [see Adverse Reactions (6.1)]. Eighty-three percent of infusion-related reactions occurred in Cycles 1 and 2. The most common symptoms included nausea, fatigue, chills, musculoskeletal pain, vomiting, fever, and arthralgia.
Premedicate patients for the first three cycles prior to starting a LYMPHIR infusion [see Dosage and Administration (2.3)]. Monitor patients frequently during infusion. For Grade 2 or higher infusion reactions, premedicate at least 30 minutes prior to each subsequent infusion with a systemic steroid for at least 3 cycles.
Interrupt or discontinue LYMPHIR based on severity [see Dosage and Administration (2.4)]. Institute appropriate medical management.
Hepatotoxicity
LYMPHIR can cause hepatotoxicity. In the pooled safety population, elevated ALT occurred in 70% of patients, with Grade 3 ALT occurring in 22%; elevated AST occurred in 64% of patients, with Grade 3 AST elevation occurring in 9%. For Grade 3 events, median time to onset was 8 days (range: 1 to 15 days); median time to resolution was 15 days (range: 7 to 50 days); all cases of Grade 3 ALT or AST elevations resolved [see Adverse Reactions (6.1)]. Elevated total bilirubin occurred in 5% of patients, with Grade 3 occurring in 0.9%.
Monitor liver enzymes and bilirubin at baseline and during treatment as clinically indicated. Withhold, reduce dose, or permanently discontinue LYMPHIR based on severity.
Embryo-Fetal Toxicity
Based on its mechanism of action, LYMPHIR can cause fetal harm when administered to a pregnant woman. Verify the pregnancy status of females of reproductive potential prior to the initiation of LYMPHIR. Advise pregnant women of the potential risk to the fetus. Advise females of reproductive potential to use effective contraception during treatment and for 7 days following the last dose of LYMPHIR.
ADVERSE REACTIONS
The most common adverse reactions (≥20%), including laboratory abnormalities, are increased transaminases, albumin decreased, nausea, edema, hemoglobin decreased, fatigue, musculoskeletal pain, rash, chills, constipation, pyrexia, and capillary leak syndrome
USE IN SPECIFIC POPULATIONS
Pregnancy
Risk SummaryBased on its mechanism of action, LYMPHIR can cause fetal harm when administered to a pregnant woman. There are no available data on the use of LYMPHIR in pregnant women to evaluate for a drug-associated risk. No animal reproductive and developmental toxicity studies have been conducted with denileukin diftitox.
Denileukin diftitox-cxdl causes depletion of regulatory T lymphocytes (Treg), immune activation, and capillary leak syndrome, compromising pregnancy maintenance. Advise pregnant women of the potential risk to a fetus.
In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies are 2-4% and 15-20%, respectively.
Lactation
Risk SummaryNo data are available regarding the presence of denileukin diftitox-cxdl in human milk, the effects on the breastfed child, or on milk production. Because of the potential for serious adverse reactions in breastfed children, advise women not to breastfeed during treatment with LYMPHIR and for 7 days after the last dose.
Females and Males of Reproductive Potential
Based on its mechanism of action, LYMPHIR can cause fetal harm when administered to a pregnant woman.
Pregnancy TestingVerify the pregnancy status of females of reproductive potential prior to initiating LYMPHIR.
Contraception
FemalesAdvise females of reproductive potential to use effective contraception during treatment with LYMPHIR and for 7 days after the last dose.
Infertility
MalesBased on findings in rats, male fertility may be compromised by treatment with LYMPHIR. The reversibility of the effect on fertility is unknown.
Pediatric UseSafety and effectiveness of LYMPHIR in pediatric patients have not been established.
Geriatric UseOf the 69 patients with Stage I-III r/r CTCL who received LYMPHIR, 34 patients (49%) were 65 years of age and older and 10 patients (14%) were 75 years of age and older. Clinical studies of LYMPHIR did not include sufficient numbers of patients 65 years of age and older to determine whether they respond differently from younger adult patients.
You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Citius Pharmaceuticals at 1-844-459-6744.
Please read Important Safety Information and full Prescribing Information, including Boxed WARNING, for LYMPHIR.
About Citius Oncology, Inc.
Citius Oncology, Inc. (Nasdaq: CTOR) is a platform to develop and commercialize novel targeted oncology therapies. In August 2024, its primary asset, LYMPHIR, was approved by the FDA for the treatment of adults with relapsed or refractory CTCL who had had at least one prior systemic therapy. Management estimates the initial market for LYMPHIR currently exceeds $400 million, is growing, and is underserved by existing therapies. Robust intellectual property protections that span orphan drug designation, complex technology, trade secrets and pending patents for immuno-oncology use as a combination therapy with checkpoint inhibitors would further support Citius Oncology's competitive positioning. For more information, please visit www.citiusonc.com.
About Citius Pharmaceuticals, Inc.
Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. In August 2024, the FDA approved LYMPHIR, a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Citius Pharma's late-stage pipeline also includes Mino-Lok®, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections, and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. A Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido were completed in 2023. Mino-Lok met primary and secondary endpoints of its Phase 3 Trial. Citius is actively engaged with the FDA to outline next steps for both programs. Citius Pharmaceuticals owns 92% of Citius Oncology. For more information, please visit www.citiuspharma.com.
Forward-Looking Statements
This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius Pharma or Citius Oncology. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "plan," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated, and, unless noted otherwise, that apply to Citius Pharma and Citius Oncology, are: our ability to commercialize LYMPHIR and any of our other product candidates that may be approved by the FDA; our need for substantial additional funds; our ability to successfully implement and maintain distribution agreements with current or other future distribution partners; potential disruptions or performance issues involving third-party logistics providers; the estimated markets for our product candidates and the acceptance thereof by any market; the ability of our product candidates to impact the quality of life of our target patient populations; risks relating to the results of research and development activities, including those from our existing and any new pipeline assets; our dependence on third-party suppliers; our ability to procure cGMP commercial-scale supply; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; the early stage of products under development; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; government regulation; competition; as well as other risks described in our SEC filings. These risks have been and may be further impacted by any future public health risks. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our Securities and Exchange Commission ("SEC") filings which are available on the SEC's website at www.sec.gov, including in Citius Oncology's and Citius Pharma's Annual Reports on Forms 10-K for the year ended September 30, 2024, filed with the SEC on December 27, 2024, as updated by our subsequent filings with the SEC. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.
Investor Contact:
Ilanit Allenir@citiuspharma.com 908-967-6677 x113
Media Contact:
STiR-communicationsGreg SalsburgGreg@STiR-communications.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/citius-oncology-enters-into-distribution-services-agreement-with-cardinal-health-302475654.html
SOURCE Citius Pharmaceuticals, Inc.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Yahoo

10 minutes ago

• Yahoo

TEGNA Appoints Three New Vice Presidents of Content

TEGNA veterans Carol Fowler and Julie Wolfe and former Univision executive Chris Peña join the company's content leadership team Carol Fowler Julie Wolfe Chris Peña TYSONS, Va., June 23, 2025 (GLOBE NEWSWIRE) -- TEGNA Inc. (NYSE: TGNA) today announced the appointment of Carol Fowler, Julie Wolfe and Chris Peña as vice presidents of content, effective June 30. These strategic appointments, which are part of TEGNA's commitment to invest in content as the company continues to build a sustainable future for local news, follow the company's recent announcement that its stations will be adding more than 100 hours of new daily streaming programming across 51 markets. In these new roles, each of the three leaders will oversee local stations in a dedicated geographic region, focusing on the quality, depth, and relevance of coverage, and emphasizing the local impact and the daily practical value of the information. Each will also oversee a content priority, such as weather coverage, big stories and events, morning news strategy, sales and sponsorships, storytelling, and investigative and solutions-based journalism. Working closely with general managers, news directors, and the newsroom staff who will maintain editorial leadership at TEGNA's local stations, the new leaders will strengthen storytelling and coverage capabilities. These new leaders will be well positioned to help identify trends and when appropriate, foster cross-station collaboration that enables journalists to produce more in-depth stories from local perspectives. 'Carol, Julie and Chris each bring deep experience building innovative newsrooms and understand the importance of strong local journalism,' said Adrienne Roark, chief content officer at TEGNA. 'They're passionate about developing talent and creating engaging content that serves viewer needs across platforms. Their leadership will be instrumental in further strengthening TEGNA's award winning content.' Longtime TEGNA newsroom leader Carol Fowler will oversee content strategy across the company's stations in the Mid-South, including St. Louis, Knoxville, Memphis, Louisville, Fort Smith, Little Rock and New Orleans. A nationally recognized digital content strategist with more than 30 years of experience, Fowler currently leads content strategy at WXIA, TEGNA's NBC affiliate in Atlanta. She also led the newsroom at TEGNA's NBC affiliate in St. Louis, where her team won 23 regional RTDNA Edward R. Murrow Awards. Throughout her career, Fowler has driven digital innovation across major media organizations including the Chicago Sun-Times, FOX and CBS owned-and-operated stations in Chicago, as well as WGN. She founded KloboMedia in 2014, pioneering the development of social media analytics software. The Mississippi native and University of Missouri-Columbia graduate taught media innovation at Northwestern's Medill School of Journalism. Julie Wolfe will oversee content strategy for TEGNA stations in the West, including Phoenix, Sacramento, San Diego, Seattle, Portland, Spokane, Boise and Denver. Wolfe currently serves as news director at KING, TEGNA's NBC affiliate in Seattle, where she has driven digital innovation and cross-platform storytelling for the station since 2021. This year, under her leadership, KING took home 11 Regional Edward R. Murrow Awards, including overall excellence. Previously, she served as news director for WHAS, TEGNA's ABC affiliate in Louisville, where she helped transform key shows, earning multiple Emmy and regional Edward R. Murrow Awards. A University of Georgia graduate, Wolfe also spent over a decade at WXIA, TEGNA's Atlanta station, progressing from multimedia journalist to assistant news director. She remains active in industry leadership, chairing RTDNA's Finance Committee and serves on multiple professional boards. Chris Peña will oversee content strategy for TEGNA's Midwest region, managing operations in Cleveland, Toledo, Columbus, Grand Rapids, Indianapolis, Des Moines, Davenport and Minneapolis. Peña currently serves as director of broadcast transformation at Blue Engine, a firm that provides coaching and consulting to media firms to foster audience growth, revenue diversification, and digital transformation. Previously, Peña was senior vice president of news at Univision Local Media, where he led multi-platform content strategy and branding across 19 television stations. Throughout his career, Peña has led all weekend live programming, including the 24-hour breaking news team for MSNBC, and notably launched NBC Latino, an innovative digital platform delivering English-language Hispanic news. Peña serves on the Consulting Council of the Consortium on Trust in Media and Technology at the University of Florida and the Journalism Council of the News Literacy Project. He holds a Bachelor of Arts degree in Radio and Television from the University of Houston and is a graduate of Columbia University's Sulzberger Executive Leadership Program in Media. About TEGNATEGNA Inc. (NYSE: TGNA) helps people thrive in their local communities by providing the trusted local news and services that matter most. With 64 television stations in 51 U.S. markets, TEGNA reaches more than 100 million people monthly across the web, mobile apps, connected TVs, and linear television. Together, we are building a sustainable future for local news. For more information, visit For media inquiries, contact:Molly McMahonSenior Director, Corporate Communications 703-873-6422mmcmahon@ For investor inquiries, contact:Julie HeskettSenior Vice President, Chief Financial Officer703-873-6747investorrelations@ Photos accompanying this announcement are available at in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Forbes

10 minutes ago

• Forbes

Side Hustle Or Salary Bump? How Gen Z And Millennials Are Doubling Their Income In 2025

In 2025, Gen Z and millennials are approaching financial growth with bold new strategies. Faced with rising living costs, shifting job security, and a changing relationship with work, many young professionals aren't waiting around for promotions or cost-of-living adjustments. They're taking income into their own hands—either by asking for more at work or by building something outside of it. While some are successfully negotiating raises, others are diving into freelance gigs or microbusinesses. So which strategy actually works better, and which one is right for you? Let's look at the data behind each approach and what Gen Z and millennials should consider when deciding how to increase their income this year. Gen Z is entering the workforce with less patience and more pragmatism. They want purpose, but they also want pay. Nearly two-thirds of 18–35-year-olds in the U.S. already have or plan to start a side hustle, driven by rising costs and gig flexibility, according to a recent Side Hustle Nation report compiling U.S. demographic data. At the same time, younger workers are becoming more assertive about their worth in traditional employment. According to NASDAQ, 55% of Gen Z negotiated their starting salary – more than any other generation. Whether through entrepreneurship or self-advocacy, the trend is clear. Young professionals are getting louder about money. 1. The salary negotiation route Best for you if: You're established in your role, want to grow internally, and prefer a stable income stream. Negotiating your salary may not be glamorous, but it's one of the most powerful tools you have to increase earnings, especially in roles where your value is proven. According to a Pew Research summary, two-thirds of people who asked for a raise received a better offer. In fact, 38% were offered more than they requested. MorningStar reports that Gen Z graduates are aiming for starting salaries between $75,000 and $100,000. Career advisors say negotiation is one of the only ways to bridge that gap early. As Forbes contributor Benjamin Laker advises, aiming for a realistic target, like a 5–10% raise, is key to negotiation success, especially when aligning your request with business goals. Pros of negotiation: Raises can compound over time, increasing long-term earnings Builds confidence and self-advocacy skills Strengthens your brand within the company Challenges: May feel uncomfortable if you lack leverage or support Requires preparation, research, and timing Doesn't solve job dissatisfaction or stalled growth If you're performing well and haven't had a compensation review recently, it may be time to start the conversation. Whether it's a bold ask at work or a business built after hours, Gen Z is taking control of how they ... More earn. getty 2. The side hustle strategy Best for you if: You want flexibility, creative freedom, or feel limited in your current role. Side hustles have evolved beyond Etsy shops and rideshare gigs. Today, they include everything from digital consulting and online tutoring to resale businesses and niche content creation. According to Scripps News, 26% of Gen Z already hold a side job. Over half expect to manage multiple income streams within the next five years. The income can be significant. A LendingTree study found the average side hustle earns around $1,200 per month, although the median is closer to $400. More importantly, 61% of respondents said their side hustle income was essential to making ends meet. Forbes recently highlighted how pairing gig roles like tutoring and content creation has helped some earn up to $5,000 per month, demonstrating what's possible when combining high-demand gigs. Pros of side hustling: Offers creative control and financial autonomy Builds marketable skills you can carry into other roles Could grow into a full-time business Challenges: Requires time and discipline outside your 9 to 5 Income can be inconsistent or delayed Risk of burnout if poorly managed If you're already spending evenings helping friends with social media or running an online store, you may be further along than you think. 3. Choosing what works for you Instead of asking which strategy is better, consider which is more realistic and beneficial for your current situation. Questions to reflect on: Do I have leverage at work or standout results I can use in a raise conversation? Is my current role a long-term fit or a stepping stone? Do I have available time, even in short blocks, to dedicate to a side project? Am I more motivated by career progression or creative ownership? Answering these questions can help point you toward a path that plays to your strengths and fits your lifestyle. 4. Can you do both? In many cases, yes. But it takes strategy. Some professionals negotiate for better pay at work while launching a consulting gig on the side. Others use their side hustle to fund certifications that increase their earning power at their day job. Done carefully, this hybrid approach can create more financial flexibility and professional momentum. Just make sure to set boundaries. Time-box your side projects. Check for conflict-of-interest clauses. And be honest with yourself about what you can sustainably manage. Take control of your income story In a job market shaped by automation and changing values, Gen Z and millennials are no longer relying on annual reviews or climbing one rigid ladder. They're carving income paths of their own—sometimes inside the office, sometimes outside of it, and often both. You don't need to pick the 'right' path. You just need to pick the one that works for you. Whether that means having a bold conversation with your manager or turning your skills into something marketable after hours, the most important step is choosing to act.

Business Wire

15 minutes ago

• Business Wire

Ameriprise Financial Donates More Than $3.5 Million to Nonprofits and Key Philanthropic Partners, Supporting Its Local Communities

MINNEAPOLIS--(BUSINESS WIRE)--Ameriprise Financial, Inc. (NYSE: AMP) today announced it has donated nearly $2 million to more than 85 nonprofits across the U.S. as part of its first-round of 2025 grants. The firm also provided an additional $1.58 million in matching donations made by its employees and advisors since the start of the year. Ameriprise is committed to supporting the communities where its people live and work by making grants primarily in its largest employee centers. The grants focus on the firm's three key giving priorities: meeting basic needs, supporting vibrant communities, and amplifying the impact of the firm's volunteers. The firm also supports its people through global gift matching to eligible 501(c)(3) nonprofits to double the impact of their donations to causes that matter most to them. 'For nearly two decades as a public company, our focus on meeting basic needs – guided by our values and rooted in respect for individuals and our communities – has never wavered,' said Jennifer Jones, head of Community Relations at Ameriprise. 'Nonprofits across the U.S. are navigating a complex and rapidly evolving landscape and rising demand. Ameriprise remains committed to consistently supporting our communities and long-standing philanthropic partnerships through grants and ongoing opportunities for giving and volunteering.' National Philanthropic Partners Along with support of local nonprofits, Ameriprise remains committed to its longstanding national philanthropic partners Feeding America © in support of hunger relief and American Red Cross for disaster relief and recovery. Along with monetary donations, Ameriprise organizes several volunteer events each year to support their national philanthropic partners. For example, in response to critically low blood donation levels, Ameriprise coordinated in-person and virtual blood drives across the nation in partnership with the American Red Cross with a set goal of donating 500 units of blood this year. About Ameriprise Financial Community Relations Ameriprise Financial is dedicated to utilizing the firm's resources and talents to improve the lives of individuals and build strong communities. Through grants, volunteerism and employee and advisor gift matching programs, the company supports more than 7,500 nonprofits globally. The company also has a longstanding commitment to volunteerism. Each year, the firm's employees are eligible for the eight hours of paid time off to volunteer. In 2024, Ameriprise volunteers collectively contributed more than 50,000 hours to nonprofits in communities across the country. About Ameriprise Financial At Ameriprise Financial, we have been helping people feel confident about their financial future for more than 130 years 1. With extensive investment advice, global asset management capabilities and insurance solutions, and a nationwide network of more than 10,000 financial advisors, we have the strength and expertise to serve the full range of individual and institutional investors' financial needs. © 2025 Ameriprise Financial, Inc. All rights reserved.